Type of Study:
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in people with type 2 diabetes
Study Length:
68 Weeks
Target Age/Sex:
over 18 years, Male and Female
Benefits:
Participants will receive at no cost: study product, study materials and study-specific procedures
Staus: Coming soon
Description:
Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in people with type 2 diabetes.
